Description

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.–20°C (Powder, sealed storage, away from moisture and light)-Applications–Formula-C39H67N5O7-Citation–References-[1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.|[2]Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.-CASNumber-474645-27-7-MolecularWeight-717.98-Compound Purity-99.98-SMILES-CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 48 mg/mL|Ethanol : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)-Target-ADC Cytotoxin;Apoptosis;Microtubule/Tubulin-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related;Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related